EWTX - CIK 0001710072
The table below shows Edgewise Therapeutics, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $33.21M | $46.00M | $43.40M | $49.92M | $44.81M | $43.48M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $509.79M |
| $573.90M |
| $603.25M |
| $443.18M |
| $499.44M |
| $519.44M |
| Property, plant & equipment | $7.40M | $8.13M | $8.60M | $8.99M | $9.97M | $9.90M |
| Goodwill | - | - | - | - | - | - |
| Total assets | $518.52M | $583.47M | $613.33M | $454.39M | $511.28M | $531.65M |
| Accounts payable | $7.29M | $6.16M | $8.32M | $8.79M | $5.65M | $6.80M |
| Total current liabilities | $22.54M | $21.65M | $20.90M | $21.11M | $18.96M | $17.18M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $25.32M | $24.82M | $24.26M | $24.67M | $22.41M | $21.17M |
| Retained earnings | -$595.38M | -$496.15M | -$455.49M | -$419.37M | -$338.91M | -$304.79M |
| Total equity | $493.20M | $558.65M | $589.07M | $429.72M | $488.88M | $510.47M |